TTM
$7.49B
YoY change
-3.1%
5Y CAGR
-3.2%
Peak year (2022)
$31.36B
Cumulative net income
$293.01B
Net Income history chart for Pfizer (PFE) from 1985 to 2025
Latest: $7.77B
Net Income growth chart for Pfizer (PFE) from 1985 to 2025
Latest: -3.1%
Net Income history table for Pfizer (PFE) from 1985 to 2025
| 2025 | $7.77B | -3.1% | −$250.00M | ||
| 2024 | $8.02B | +276.0% | +$5.89B | ||
| 2023 | $2.13B | -93.2% | −$29.23B | ||
| 2022 | $31.36B | +41.6% | +$9.22B | ||
| 2021 | $22.15B | +141.8% | +$12.99B | ||
| 2020 | $9.16B | -43.7% | −$7.11B | ||
| 2019 | $16.27B | +45.9% | +$5.12B | ||
| 2018 | $11.15B | -47.7% | −$10.15B | ||
| 2017 | $21.30B | +195.3% | +$14.09B | ||
| 2016 | $7.21B | +3.6% | +$249.00M | ||
| 2015 | $6.97B | -23.3% | −$2.11B | ||
| 2014 | $9.08B | -22.1% | −$2.57B | ||
| 2013 | $11.65B | +19.0% | +$1.86B | ||
| 2012 | $9.79B | +12.4% | +$1.08B | ||
| 2011 | $8.71B | +5.3% | +$437.00M | ||
| 2010 | $8.27B | -4.3% | −$367.00M | ||
| 2009 | $8.63B | +7.6% | +$611.00M | ||
| 2008 | $8.02B | -2.3% | −$186.00M | ||
| 2007 | $8.21B | -25.5% | −$2.81B | ||
| 2006 | $11.02B | +44.9% | +$3.41B | ||
| 2005 | $7.61B | -32.8% | −$3.72B | ||
| 2004 | $11.33B | +189.8% | +$7.42B | ||
| 2003 | $3.91B | -57.2% | −$5.22B | ||
| 2002 | $9.13B | +17.2% | +$1.34B | ||
| 2001 | $7.79B | +109.0% | +$4.06B | ||
| 2000 | $3.73B | +17.2% | +$547.00M | ||
| 1999 | $3.18B | -5.1% | −$172.00M | ||
| 1998 | $3.35B | +51.4% | +$1.14B | ||
| 1997 | $2.21B | +14.7% | +$284.00M | ||
| 1996 | $1.93B | +22.6% | +$356.10M | ||
| 1995 | $1.57B | +21.1% | +$274.50M | ||
| 1994 | $1.30B | +97.5% | +$640.90M | ||
| 1993 | $657.50M | -18.9% | −$153.40M | ||
| 1992 | $810.90M | +12.3% | +$88.80M | ||
| 1991 | $722.10M | -9.9% | −$79.10M | ||
| 1990 | $801.20M | +17.6% | +$120.10M | ||
| 1989 | $681.10M | -13.9% | −$110.20M | ||
| 1988 | $791.30M | +14.6% | +$101.10M | ||
| 1987 | $690.20M | +4.6% | +$30.20M | ||
| 1986 | $660.00M | +13.9% | +$80.30M | ||
| 1985 | $579.70M | — | — |
- 2025$7.77B-3.1%
- 2024$8.02B+276.0%
- 2023$2.13B-93.2%
- 2022$31.36B+41.6%
- 2021$22.15B+141.8%
- 2020$9.16B-43.7%
- 2019$16.27B+45.9%
- 2018$11.15B-47.7%
- 2017$21.30B+195.3%
- 2016$7.21B+3.6%
- 2015$6.97B-23.3%
- 2014$9.08B-22.1%
- 2013$11.65B+19.0%
- 2012$9.79B+12.4%
- 2011$8.71B+5.3%
- 2010$8.27B-4.3%
- 2009$8.63B+7.6%
- 2008$8.02B-2.3%
- 2007$8.21B-25.5%
- 2006$11.02B+44.9%
- 2005$7.61B-32.8%
- 2004$11.33B+189.8%
- 2003$3.91B-57.2%
- 2002$9.13B+17.2%
- 2001$7.79B+109.0%
- 2000$3.73B+17.2%
- 1999$3.18B-5.1%
- 1998$3.35B+51.4%
- 1997$2.21B+14.7%
- 1996$1.93B+22.6%
- 1995$1.57B+21.1%
- 1994$1.30B+97.5%
- 1993$657.50M-18.9%
- 1992$810.90M+12.3%
- 1991$722.10M-9.9%
- 1990$801.20M+17.6%
- 1989$681.10M-13.9%
- 1988$791.30M+14.6%
- 1987$690.20M+4.6%
- 1986$660.00M+13.9%
- 1985$579.70M—
Net Income values are taken from Pfizer's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Net Income at Pfizer (PFE)
According to Pfizer's latest reported financial statements, the company's current net income (TTM) is $7.49B. Net income is the bottom-line profit after all expenses — cost of goods sold, operating expenses, interest, and taxes — are subtracted from revenue. It is the figure used to compute earnings per share (EPS) and is the residual available to shareholders.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Pfizer (PFE) net income is $7.77B – edged down 3.1% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Pfizer net income compounded at -3.2% per year, with a net decline across the window.
Pfizer net income peaked at $31.36B in 2022; the latest annual figure is $7.77B in 2025 (75.2% below peak).
The record annual net income stands at $31.36B, reached in 2022; the historical low of $579.70M was recorded in 1985.
Pfizer Net Income by Year
Pfizer Net Income 2025: $7.77B
Pfizer posted net income of $7.77B in 2025, edged down 3.1% below 2024.
Pfizer Net Income 2024: $8.02B
In 2024, Pfizer reported net income of $8.02B, surged 276.0% from 2023.
Pfizer Net Income 2023: $2.13B
Pfizer net income in 2023 was $2.13B, plunged 93.2% below 2022.
Pfizer Net Income 2022: $31.36B
2022's net income for Pfizer came in at $31.36B, surged 41.6% from 2021. This figure represents the highest annual value in the available history.
Pfizer Net Income 2021: $22.15B
Pfizer net income in 2021 was $22.15B.
See more financial history for Pfizer (PFE).
Sector peers by Net Income
Healthcare peers of Pfizer (PFE), ranked by their latest net income
| $26.80B | |
| $20.64B | |
| $18.25B | |
| $15.97B | |
| $12.06B | |
| $10.26B | |
| $7.71B | |
| $4.23B |
- $26.80B
- $20.64B
- $18.25B
- $15.97B
- $12.06B
- $10.26B
- $7.71B
- $4.23B
Frequently asked questions
Pfizer (PFE) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation